Coldea Bianca Maria, Middleton Lucille, Aiken Catherine, Bhagra Catriona J
Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK.
University of Nottingham, Nottingham, UK.
JRSM Cardiovasc Dis. 2025 Jul 14;14:20480040251352901. doi: 10.1177/20480040251352901. eCollection 2025 Jan-Dec.
Cardiomyopathies are diseases of the heart muscle, characterised by structural and functional abnormalities of the myocardium that are not caused by ischemia, valvular problems or congenital heart disease. They are responsible for one-third of pregnancy-related cardiovascular deaths. A woman may enter pregnancy with a pre-existing diagnosis, or the cardiomyopathy may emerge or develop de novo during pregnancy. The most common cardiomyopathies encountered in pregnancy are dilated cardiomyopathy, hypertrophic cardiomyopathy and peripartum cardiomyopathy. All cardiomyopathies can be complicated by clinical heart failure, arrhythmia and thromboembolic events. Pregnancy may be poorly tolerated in women with dilated cardiomyopathy. New York Heart Association Class (NYHA) III/IV symptoms, and severe left ventricular dysfunction are the main determinants of adverse maternal outcomes. Peripartum cardiomyopathy is a diagnosis of exclusion with symptom onset towards the end of pregnancy, or within a few months following delivery. The management of heart failure and arrhythmias is based upon established guidelines, tailored for the unique considerations of pregnancy. Contemporary data suggests that recovery in cardiac function by 12 months is approximately 60-70% for the peripartum group. Maternal cardiovascular risk can be determined using specific risk-predictive scores. All patients with cardiomyopathy who wish to consider pregnancy should be offered individualized pre-conception and contraceptive counselling by a multidisciplinary team. This article reviews the management of women with cardiomyopathy during pregnancy and breastfeeding, focusing on the essential role of the multidisciplinary team at every stage of pregnancy and postpartum period to improve the maternal, fetal, and neonatal outcomes.
心肌病是心肌疾病,其特征为心肌的结构和功能异常,且并非由缺血、瓣膜问题或先天性心脏病引起。它们占妊娠相关心血管死亡的三分之一。女性可能在已有诊断的情况下怀孕,或者心肌病可能在孕期新发或进展。孕期最常见的心肌病是扩张型心肌病、肥厚型心肌病和围产期心肌病。所有心肌病都可能并发临床心力衰竭、心律失常和血栓栓塞事件。扩张型心肌病女性对妊娠的耐受性可能较差。纽约心脏协会心功能分级(NYHA)III/IV级症状以及严重左心室功能障碍是不良孕产妇结局的主要决定因素。围产期心肌病是一种排除性诊断,症状出现在妊娠末期或分娩后数月内。心力衰竭和心律失常的管理基于既定指南,并针对妊娠的特殊考虑因素进行调整。当代数据表明,围产期心肌病组在12个月内心脏功能恢复的比例约为60 - 70%。可使用特定的风险预测评分来确定孕产妇心血管风险。所有希望考虑怀孕的心肌病患者都应由多学科团队提供个性化的孕前和避孕咨询。本文综述了孕期和哺乳期心肌病女性的管理,重点关注多学科团队在孕期和产后各阶段的重要作用,以改善孕产妇、胎儿和新生儿结局。